PATENT CLAIM ANALYSIS

Application Number: 15990035
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["514", "265100"]

Abstract:
The present invention relates to a liquid pharmaceutical composition suitable for parenteral administration comprising: a) pemetrexed diacid; b) at least one organic amine; c) at least one antioxidant; d) 10-200 mg/ml of propylene glycol; and e) one or more parenteral solvents, wherein the preparation thereof is conducted in an atmosphere of inert gas and wherein the organic amine(s) is present in an amount sufficient to reach a pH of the composition in the range from 8.3 to 9.1  The invention further relates to the use of said liquid pharmaceutical composition as medicament in the treatment of malignant pleural mesothelioma and non-small cell lung cancer.

Claim (Index 20):
The liquid pemetrexed pharmaceutical composition according to  claim 19 , wherein said monothiolic antioxidant is L-cysteine and said L-cysteine is present in said composition in a concentration of 0.5-4 mg/ml.

Metadata:
- Claim Count in Document: 46.0
- Percentile: 93.0
- Lexical Diversity: 1.60811
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15200433', '15989751', '14403310', '13806624', '15561118']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7292733363369419
- 35 USC 102 Novelty (BERT): 0.5035717789663667
- Combined Prediction Score: 0.7067031805998844
- Mean Citation Score: 191.312572
- Max Citation Score: 212.63045
- Similarity Product: 145.96597795904282

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test